UBS Group’s Tenax Therapeutics TENX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.43M | Sell |
98,143
-283,276
| -74% | -$3.62M | ﹤0.01% | 5416 |
|
|
2026
Q1 | $6.1M | Buy |
381,419
+380,743
| +56,323% | +$5.15M | ﹤0.01% | 3848 |
|
|
2025
Q4 | $8.24K | Buy |
676
+557
| +468% | +$4.84K | ﹤0.01% | 8382 |
|
|
2025
Q3 | $906 | Buy |
119
+105
| +750% | +$641 | ﹤0.01% | 9500 |
|
|
2025
Q2 | $81 | Sell |
14
-2,879
| -100% | -$16.6K | ﹤0.01% | 10017 |
|
|
2025
Q1 | $18.9K | Buy |
2,893
+2,890
| +96,333% | +$18.5K | ﹤0.01% | 8270 |
|
|
2024
Q4 | $18 | Sell |
3
-685
| -100% | -$3.32K | ﹤0.01% | 9781 |
|
|
2024
Q3 | $2.38K | Sell |
688
-811
| -54% | -$2.94K | ﹤0.01% | 8442 |
|
|
2024
Q2 | $4.52K | Buy |
1,499
+115
| +8% | +$407 | ﹤0.01% | 8079 |
|
|
2024
Q1 | $5.87K | Buy |
+1,384
| New | +$10.6K | ﹤0.01% | 7500 |
|
|
2023
Q1 | – | Sell |
-101
| Closed | -$17.7K | – | 10361 |
|
|
2022
Q4 | $17.7K | Buy |
+101
| New | +$22.2K | ﹤0.01% | 7803 |
|
|
2022
Q3 | – | Hold |
0
| – | – | – | 10917 |
|
|
2022
Q2 | – | Hold |
0
| – | – | – | 10937 |
|
|
2022
Q1 | – | Sell |
-3
| Closed | -$3.34K | – | 10888 |
|
|
2021
Q4 | $5K | Buy |
+3
| New | +$6.76K | ﹤0.01% | 9417 |
|
|
2021
Q3 | – | Sell |
-1
| Closed | -$2.62K | – | 10077 |
|
|
2021
Q2 | $2K | Hold |
1
| – | – | ﹤0.01% | 8980 |
|
|
2021
Q1 | $2K | Sell |
1
-5
| -83% | -$17.8K | ﹤0.01% | 8644 |
|
|
2020
Q4 | $17K | Buy |
+6
| New | +$11K | ﹤0.01% | 7063 |
|
|
2020
Q3 | – | Hold |
0
| – | – | – | 8400 |
|
|
2020
Q2 | – | Sell |
-1
| Closed | -$1.47K | – | 8347 |
|
|
2020
Q1 | $1K | Buy |
+1
| New | +$1.76K | ﹤0.01% | 7802 |
|
|
2019
Q4 | – | Sell |
-6
| Closed | -$11.7K | – | 8398 |
|
|
2019
Q3 | $11K | Buy |
6
+5
| +500% | +$10.4K | ﹤0.01% | 7116 |
|
|
2019
Q2 | $2K | Sell |
1
-3
| -75% | -$7.26K | ﹤0.01% | 7634 |
|
|
2019
Q1 | $12K | Sell |
4
-1
| -20% | -$2.28K | ﹤0.01% | 6696 |
|
|
2018
Q4 | $10K | Buy |
5
+4
| +400% | +$22K | ﹤0.01% | 7242 |
|
|
2018
Q3 | $12K | Sell |
1
-1
| -50% | -$9.44K | ﹤0.01% | 7075 |
|
|
2018
Q2 | $19K | Buy |
2
+1
| +100% | +$10.1K | ﹤0.01% | 6740 |
|
|
2018
Q1 | $11K | Buy |
+1
| New | +$11.5K | ﹤0.01% | 6817 |
|
|
2017
Q4 | – | Hold |
0
| – | – | – | 7547 |
|
|
2017
Q3 | – | Hold |
0
| – | – | – | 7158 |
|
|
2017
Q2 | – | Hold |
0
| – | – | – | 6726 |
|
|
2016
Q3 | – | Hold |
0
| – | -$9K | – | 7930 |
|
|
2016
Q2 | – | Hold |
0
| – | – | – | 6848 |
|
|
2016
Q1 | – | Hold |
0
| – | – | – | 8161 |
|
|
2015
Q4 | – | Hold |
0
| – | – | – | 6666 |
|
|
2015
Q3 | – | Hold |
0
| – | – | – | 6973 |
|
|
2015
Q2 | – | Hold |
0
| – | – | – | 7711 |
|
|
2015
Q1 | – | Hold |
0
| – | – | – | 7730 |
|
|
2014
Q4 | – | Hold |
0
| – | – | – | 7748 |
|
Other funds holding TENX
VC
PA
IC
CS
RI
UBS Group's TENX Position: Q2 2026 in Review
UBS Group reduced its Tenax Therapeutics (TENX) stake by 74% in Q2 2026, selling an estimated $3.62M and leaving 98,143 shares worth $1.43M. The position accounts for ﹤0.01% of the portfolio, ranked #5416.
UBS Group first reported a position in TENX in Q1 2018 and has held it in 23 quarters since. The position peaked at $6.1M in Q1 2026. 111 funds tracked by Wall St. Rank hold TENX as of Q2 2026.
- UBS Group held 98,143 shares of Tenax Therapeutics worth $1.43M as of Q2 2026.
- UBS Group sold 283,276 Tenax Therapeutics shares in Q2 2026, an estimated $3.62M.
- Tenax Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5416 holding.
- UBS Group first reported a position in Tenax Therapeutics in Q1 2018 and has held it in 23 quarters since.
- UBS Group's Tenax Therapeutics position peaked at $6.1M in Q1 2026.
- 111 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.